To restore independence using technology and innovation to empower every body forward.

IT'S A FIRST!   Introducing the first brace device with shoulder assist! Contact us to learn more!

Circle of abilities - Daily living, socialization, part of the workforce

About AbiliTech Medical


to allow those with upper-limb neuromuscular conditions to function independently.

In 2016, AbiliTech Medical, Inc. was founded by a group of deeply committed and knowledgeable individuals experienced with upper-limb impairments. Every day we strive to create and build solutions that restore function and independence to those affected by neuromuscular conditions.

The AbiliTech Assist will be the first in-home device on the market that will provide functional assistance and support to both the elbow and shoulder. This device has the potential to improve the lives of approximately 90,000 people in the United States affected by muscular dystrophy.

The AbiliTech Assist allows patients to:

  • Perform independent activities of daily living
  • Engage within their communities
  • Live independently

Meet the Team

Who We Serve

Neuromuscular conditions rob patients of their physical strength, independence, and ability to actively engage with their friends and family. Pediatric patients suffering from rare orphan medical conditions are especially in need of solutions. Patients and families undergo significant financial burden in caring for a loved one’s condition. The AbiliTech Assist can help.

patient population


Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, is a progressive fatal neurodegenerative disease involving motor neurons in the cerebral cortex, brainstem, and spinal cord. With the death of motor neurons, the ability of the brain to initiate and control muscle movement is lost. With voluntary muscle action progressively affected, people may lose the ability to speak, eat, move, and breathe.

  • More than 20,000 Americans have the disease
  • Primarily diagnosed between ages 40-70

References: DynaMed Plus - Amyotrophic lateral sclerosis (ALS) and US National Library of Medicine National Institutes of Health


Brachial plexus injury (BPI) is a disorder affecting the nerve fiber network that supplies innervation to the upper extremity and shoulder.
 Many patients experience motor weakness in the shoulder and arm and may also have pain preventing functional use of their upper extremities. Causes of Brachial plexus injury can include trauma, tumors, radiation injury, and inflammatory syndromes. Patient recovery varies and depends on the cause of injury.

  • Vehicular and motorcycle accidents account for the most common cause of BPI.
  • Approximately 17,000 patients each year experience Brachial plexus injuries that result in upper limb impairment that is not corrected by surgical or other interventions.

References: DynaMed Plus - Brachial Plexopathy


Duchenne muscular dystrophy (DMD) is a genetic disorder resulting in progressive muscle degeneration and weakness. Onset typically occurs between ages 2 and 5 with children experiencing a marked delay in meeting motor and development milestones. Unable to live normal lives because of progressive and irreversible muscle loss, patients are typically wheelchair-bound by their early teens.

  • 20,000 new cases each year worldwide

References:  DynaMed Plus - Duchenne Muscular Dystrophy


Multiple sclerosis (MS) is an autoimmune and neurodegenerative disease of the brain and spinal cord that results in neurologic dysfunction due to attack of the body’s immune system on its nerve fibers. Symptoms vary widely due to severity of disease, but patients may experience weakness in one or more limbs, vision impairment, tremors or a lack of coordination, slurred speech, dizziness, and fatigue amongst others.

  • Most commonly affects people between the ages of 15 and 60
  • Multiple sclerosis is thought to affect more than 2.3 million people worldwide
  • The average person in the United States has about one in 750 chance of developing MS

References: DynaMed Plus - Multiple Sclerosis


Spinal cord injuries (SCI) can be caused by a variety of activities, and the severity of the resulting disability is heavily reliant on the location of the spinal lesion. Injury to the C5, C6, or C7 regions of the spinal cord results in impairment in upper limbs.

  • Adults with spinal cord injuries face barriers to economic participation, with a global unemployment rate of more than 60%.
  • The level and severity of the injury have an important influence on costs—injuries higher up on the spinal cord (e.g. tetraplegia vs. paraplegia) incur higher costs.
  • Direct costs are highest in the first year after spinal cord injury onset and then decrease significantly over time.
  • Indirect costs, in particular lost earnings, often exceed direct costs. Much of the cost is borne by people with spinal cord injuries.
  • Costs of spinal cord injury are higher than those of comparable conditions such as dementia, multiple sclerosis, and cerebral palsy.
  Average Yearly Expense (in 2014 dollars) Estimated Lifetime Costs by Age At Injury (Discounted by 2%)
Severity of Injury First Year Second Year 25-Years-Old 50-Years-Old
High Tetraplegia (C1-C4) AIS ABC $1,064,716 $184,891 $4,724,181 $2,596,329
Low Tetraplegia (C5-C8) AIS ABC $769,351 $113,423 $3,451,781 $2,123,154
Perapleiga AIS ABC $518,904 $68,739 $2,310,104 $1,516,052
Motor Functional at Any Level AIS D $347,484 $42,206 $1,578,274 $1,113,990

Data Source: Economic Impact of SCI published in the journal Topics in Spinal Cord Injury Rehabilitation, Volume 16, Number 4, in 2011. ASIA Impairment Scale (AIS) is used to grade the severity of a person's neurological impairment following a spinal cord injury.

References: 1. National Spinal Cord Injury Statistical Center 2. World Health Organization 3. Topics in Spinal Cord Injury Rehabilitation


As the leading genetic cause of death in infants and toddlers, spinal muscular atrophy (SMA) is a group of genetic disorders characterized by progressive degeneration of spinal cord and brainstem motor neurons resulting in low muscle tone, atrophy of skeletal muscles, and generalized weakness.

  • SMA has generally been believed to affect as many as 10,000 to 25,000 children and adults in the United States, and therefore it is one of the most common rare diseases.
  • Department of Defense Military Healthcare System (MHS) data from 2003–2012 in the US found median annual expenditures across all years of data for patients with SMA were $83,652 with major cost drivers due to outpatient visits.

References: SMA Foundation and Taylor & Francis


The total estimated cost of illness to the nation for ALS, DMD, and MMD combined is $1.07 to $1.37 billion per year.

  • ALS $256-$433 million
  • DMD $362-$488 million
  • MMD $448 million

The per-patient annual costs for ALS, DMD, and MMD are as follows:

Disease Medical Costs Nonmedical Costs Lost Income Total
ALS (Amyotrophic lateral sclerosis) $31,121 $17,889 $14,682 $63,692
DMD (Duchenne muscular dystrophy) $22,533 $12,939 $15,481 $50,953
MMD or DM (Myotonic 
$17,451 $5,157 $9,628 $32,236

References: Muscular Dystrophy Association (MDA)

2018 MN Cup Semifinalists!

AbiliTech Medical is proud to announce it has been selected as a semifinalist in the 2018 MN Cup startup competition. MN Cup is the largest startup competition in the USA and finalists have raised over $280M in funding.

Read More


We'd like to talk to you!

We look forward to sharing the unique qualities which make our product a one-of-a-kind solution for many people with neuromuscular disorders.